The clinical stakes are considerable. Vaccines remain among the most powerful tools in public health, yet people vary enormously in how their bodies respond to them. Fever and flu-like symptoms are among the most commonly reported adverse reactions, and they are particularly frequent with mRNA vaccines and other formulations that use lipid nanoparticles to deliver their payload. These reactions are generally short-lived, but they are not trivial in their consequences. People who experience a rough forty-eight hours after a first dose are more likely to hesitate before a second, and vaccine hesitancy, once seeded, spreads through communities faster than any pathogen. Understanding who is at risk, and why, has therefore become a genuine research priority.

One puzzling observation framed the new investigation: not everyone who receives the same vaccine develops a fever, and those who do tend to develop one repeatedly, across successive doses. That pattern strongly suggested the existence of stable individual risk factors rather than chance variation. The immune system’s baseline state, shaped over years by genetics, environment, and the microbes it coexists with, seemed a likely place to look. The gut microbiome stood out as a candidate because it is known to tune immune activity throughout the body, priming inflammatory pathways and calibrating how the immune system responds to molecular signals it encounters.

To test this hypothesis, Huus and colleagues assembled a cohort of 171 healthy adults and profiled them with unusual thoroughness. Before and after receiving the mRNA vaccine against SARS-CoV-2, participants provided fecal samples for microbiome sequencing, had their body temperatures monitored, and gave blood samples for the measurement of immune markers circulating in plasma. This longitudinal design allowed the researchers to ask a specific question: did features of the gut ecosystem present before vaccination predict who would mount the inflammatory response that produces fever afterward?

The answer, in short, was yes. Participants who entered the study with greater intestinal inflammation were more likely to develop vaccine-induced fever. So were those whose guts harbored higher levels of flagellin expression, flagellin being the protein that forms the whiplike tails many bacteria use to swim. The key contributors belonged to Lachnospiraceae, a family of common gut bacteria. Flagellin is not merely a structural protein; it is also a molecular pattern that the immune system recognizes through dedicated receptors, activating inflammatory signaling cascades. In effect, certain gut residents were already holding the immune system’s alarm system partially depressed, and the vaccine’s arrival pushed it over the threshold that registers as fever.

The mechanistic picture that emerges is one of priming rather than causation in the simple sense. The vaccine does not create the inflammatory tendency; it reveals it. A gut microbiome rich in flagellin-producing Lachnospiraceae, operating in an environment of low-grade intestinal inflammation, establishes a baseline of immune activation. When the vaccine delivers its antigen and its lipid nanoparticle adjuvant effects, the systemic inflammatory response that follows is stronger in these individuals, strong enough to produce the fever and malaise that many recipients dread. In others, with different microbial profiles, the same vaccine triggers a quieter reaction.

Where does that microbial profile come from? The study’s dietary findings offer a provocative clue. Industrialized diets, the researchers found, appear to promote the inflammatory, fever-associated microbiome. Lower consumption of whole plant foods, along with eating patterns characterized by higher fat intake or greater reliance on processed foods, was associated with microbiome features linked to vaccine fever. Vegetarian diets, by contrast, correlated with microbiome characteristics that contributed to less fever. The fiber-rich substrates that plant foods supply are known to nourish gut bacteria that produce short-chain fatty acids, compounds with broadly anti-inflammatory effects on the intestinal lining, and the new data suggest this well-studied axis extends all the way to how the body tolerates vaccination.

Crucially, the researchers showed that dietary manipulation altered both microbiome composition and the vaccine responses associated with it, demonstrating that the relationship is not a fixed trait but a modifiable one. Even more important is what the study did not find. Flagellin, intestinal inflammation, and diet did not affect antibody responses to the vaccine. The microbiome-driven inflammation amplified side effects without touching the immunity that matters. This separation is the study’s most consequential finding, because it means the inflammatory and protective arms of the vaccine response can, in principle, be decoupled. A person could one day reduce their fever risk without sacrificing one iota of protection against infection.

That possibility is captured in an accompanying Perspective by Bali Pulendran, who writes that diet, microbial ecology, and metabolic state are not immutable, and that people might one day prepare for vaccination as deliberately as the vaccine itself is formulated. The image is striking: pre-vaccination protocols that include dietary adjustments or microbiome-targeted interventions, prescribed with the same care as the dose schedule itself. Such interventions remain speculative, and the study establishes associations and mechanisms in a defined cohort rather than prescribing clinical practice. But the direction of travel is clear, and the tools required, from dietary counseling to microbiome profiling, already exist in some form.

The broader lesson reaches beyond mRNA vaccines and beyond fever. The human body is not a passive container into which medicine is poured; it is an ecosystem whose resident organisms and metabolic state shape every pharmacological and immunological encounter. This study adds vaccination, one of medicine’s most standardized interventions, to the growing list of outcomes that individualize at the level of the microbiome. It also reframes an old complaint. The fever that follows a shot is not the vaccine misfiring, but a conversation between the vaccine and the trillions of microbes that were there first. Learning to conduct that conversation, through diet and microbial stewardship, could make vaccination gentler for millions of people while leaving its protective power fully intact.

Subject of Research: Influence of the human gut microbiome and diet on fever side effects after mRNA vaccination

Article Title: The human gut microbiome shapes vaccine side effects

Article References: The human gut microbiome shapes vaccine side effects. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: gut microbiome, vaccine side effects, fever, mRNA vaccines, Lachnospiraceae, flagellin, diet, inflammation, antibody response, vaccine hesitancy, Science journal, immunology

A team led by Heng Xue, Xinfeng Li, Guibo Rao, and Hang Yang, working with colleagues including Krystyna Dąbrowska of the Polish Academy of Sciences, focused on AbP20, a podovirus that infects Acinetobacter baumannii, a pathogen notorious for its resistance to last-resort antibiotics. Using a mouse infection model, the researchers asked a deceptively simple question: when the body produces antibodies against a therapeutic phage, which of those antibodies actually matter for treatment outcome? The answer, they found, is far from uniform across the viral particle.

The experimental design began with repeated intraperitoneal administration of AbP20, given once daily for seven consecutive days. This dosing regimen induced a robust phage-specific antibody response in the animals, and those antibodies measurably impaired phage therapy. Rather than treating the antibody response as a single entity, however, the team dissected it at the level of individual viral structural proteins, using a genome-guided antigen screening strategy to determine which components of the virion provoked the most therapeutically damaging immune reactions.

The screening results pointed decisively to two proteins: the nozzle and the fiber. Antibodies elicited by these two structural components, rather than those directed against the portal, the capsid, or the adaptor proteins, emerged as the dominant drivers of phage therapy failure in the mouse model. This specificity is significant because it suggests that the immunological vulnerability of a therapeutic phage is not distributed evenly across its architecture but concentrated in the machinery the virus uses to recognize and penetrate its bacterial host.

The mechanistic follow-up experiments clarified why these two proteins matter so much. Fiber-specific antibodies were found to block bacterial adsorption, the initial step in which the phage attaches to receptors on the surface of Acinetobacter baumannii. Without attachment, the infection cycle cannot begin. Nozzle-specific antibodies, by contrast, acted at a later stage, blocking genomic injection, the moment when the phage delivers its DNA into the bacterial cell. In other words, the two antibody populations sabotage the phage at two distinct and sequential checkpoints of the infection process, one preventing docking and the other preventing entry.

But neutralization inside the dish was only half of the story. The researchers discovered that both fiber-specific and nozzle-specific antibodies also promoted the formation of large phage aggregates in circulation. These antibody-mediated aggregates potentiated phagocytosis by macrophages, the scavenger cells of the immune system, and notably this enhancement occurred through an Fc receptor-independent pathway. That detail is mechanistically important: it implies that the immune clearance of antibody-coated phages does not rely on the classical Fc-mediated uptake route, pointing instead to an alternative mechanism by which macrophages recognize and engulf aggregated viral particles.

The dual action of these antibodies, blocking infection on one hand and accelerating immune clearance on the other, constitutes a synergistic assault on therapeutic efficacy. A phage that cannot attach to or inject into its target bacterium is already crippled, and the same antibodies simultaneously shorten the window of time the phage survives in the body by hastening its removal. The study’s authors describe this as a dual synergistic mechanism through which nozzle- and fiber-elicited neutralizing antibodies impair phage therapy, a framing that captures how the two effects compound rather than merely add together.

To probe whether escaping neutralization could rescue treatment, the team turned to an evolved AbP20 variant with improved neutralization escape capacity. The results were instructive but sobering. This variant exhibited antibody-accelerated phagocytosis and host immune clearance comparable to the parental phage, meaning that evolving away from antibody recognition did not spare it from the clearance arm of the immune response. Nevertheless, the variant partially rescued the therapeutic failure caused by neutralizing antibodies, indicating that the infection-blocking effect is the more decisive contributor to treatment loss, while immune clearance imposes a persistent background cost that escape mutations do not readily evade.

The broader implications for phage therapy development are considerable. Clinical phage programs typically monitor neutralizing antibody titers as a single aggregate measure, but this study suggests that the protein specificity of the antibody response is what ultimately shapes therapeutic outcomes. If antibodies against the portal, capsid, or adaptor proteins are comparatively benign while fiber- and nozzle-directed antibodies are the dominant saboteurs, then rational phage engineering, careful phage selection, or dosing strategies that minimize exposure of the receptor-binding apparatus to the immune system could meaningfully extend the viability of phage treatments in patients who mount strong antibody responses.

For a field racing to keep pace with antimicrobial resistance, the findings offer both a warning and a roadmap. The warning is that repeated phage dosing, a common feature of current treatment protocols, can provoke antibody responses that quietly dismantle therapeutic efficacy through mechanisms that standard efficacy testing may not capture. The roadmap lies in the molecular detail: by identifying the nozzle and fiber proteins as the principal immunological weak points of AbP20, the study provides a concrete framework for predicting which phages are most likely to fail under immune pressure and for designing next-generation therapeutics that either evade these antibodies or tolerate their presence well enough to complete the job.

Subject of Research: Antibody specificity in phage therapy failure against Acinetobacter baumannii

Article Title: Antibodies targeting phage fiber and nozzle proteins impair Acinetobacter baumannii phage therapy by blocking infection and promoting immune clearance

Article References: Xue, H., Li, X., Rao, G., Hu, F., Zhong, M., Miernikiewicz, P., Qiu, R., Cao, S., Dąbrowska, K., & Yang, H. (2026). Antibodies targeting phage fiber and nozzle proteins impair Acinetobacter baumannii phage therapy by blocking infection and promoting immune clearance. PLOS Biology, 24(9), e3004009. https://doi.org/10.1371/journal.pbio.3004009

Image Credits: AI Generated

DOI: 10.1371/journal.pbio.3004009

Keywords: phage therapy, Acinetobacter baumannii, antimicrobial resistance, neutralizing antibodies, fiber protein, nozzle protein, macrophage phagocytosis, podovirus, immune clearance, PLOS Biology, phage aggregates, Fc receptor-independent pathway

The scale of the public health problem behind this work is difficult to overstate. Plasmodium vivax is the second most prevalent of the human malaria parasites, and an estimated 2.5 billion people live in regions where they are at risk of infection. Each year, around 10 million clinical cases of vivax malaria occur, producing debilitating febrile illness and a substantial burden of relapsing disease, because the parasite can hide in the liver in a dormant hypnozoite form and re-emerge weeks or months later to trigger new blood-stage infections. Unlike its better-studied cousin Plasmodium falciparum, which dominates mortality statistics in sub-Saharan Africa, P. vivax has been comparatively neglected by vaccine developers, in part because it is extraordinarily difficult to culture continuously in the laboratory. That technical barrier has starved researchers of the material they need to systematically test which parasite proteins the human immune system actually targets during natural infection.

The new study attacks that knowledge gap head-on with a technology that sidesteps the need to grow the parasite at all. Rather than expressing and purifying full-length P. vivax proteins, the researchers synthesized the entire proteome as short linear peptides arrayed at extremely high density on a solid support. Each protein sequence was tiled as overlapping fragments, so that any antibody raised against any linear epitope anywhere in the parasite’s proteome would have a corresponding binding partner on the array. Serum samples from individuals with symptomatic vivax malaria and from malaria-naïve controls were applied to the array, and antibody binding was quantified for each of the 4.2 million features. This agnostic, proteome-wide design means the results are not biased toward previously studied antigens or proteins that are easy to express; every gene in the parasite gets an equal chance to reveal itself as a target of the human antibody response.

The headline result is a curated list of 283 P. vivax proteins that are commonly immunogenic across symptomatic individuals. Consistency across patients is the key filter here: many proteins might be recognized by antibodies in one or two donors, but the 283 that emerged were repeatedly targeted in multiple infected individuals, making them robust candidates for further study. Among them were numerous proteins already known or suspected to participate in erythrocyte invasion, the critical step at which merozoites released from infected liver cells or red blood cells recognize, attach to, and enter new red blood cells to propagate the blood-stage infection. Invasion-related proteins have long been considered prime vaccine candidates because blocking them could prevent the parasite from amplifying within the bloodstream, so their prominence in the natural antibody response reinforces their status as priority targets.

Perhaps more intriguing are the surprises. The screen surfaced several nucleoporins, components of the nuclear pore complexes that regulate traffic between the parasite’s nucleus and cytoplasm. Antibodies against these internal housekeeping proteins were not an obvious expectation, and their detection suggests that during symptomatic infection the immune system is exposed to parasite material well beyond the small set of surface proteins traditionally assumed to be the main antibody targets. Whether these responses are merely a byproduct of parasite destruction and antigen release, or whether they carry functional consequences for infection, remains an open question. The study also flagged a large number of proteins of completely unknown function, annotated only as hypothetical or uncharacterized. These proteins, now shown to be immunogenic in symptomatic patients, represent a rich vein for future research, since their antibody recognition implies they are produced and accessible during blood-stage infection even though their biological roles have never been defined.

The comparison between symptomatic and asymptomatic individuals produced what may be the study’s most consequential finding. People who carried the parasite without developing clinical symptoms showed a distinctive pattern of antibody responses against the PIR family of proteins, a large and variable group of P. vivax-specific antigens whose functions are still being untangled. The authors suggest that this unique PIR-focused antibody profile in asymptomatic individuals could be associated with protection against clinical vivax malaria. If that association holds up under further scrutiny, it would offer a molecular clue to how some people tolerate infection without illness, and it would elevate specific PIR proteins as candidates for serological markers that distinguish protective immunity from mere exposure. It could also inform vaccine design, since a vaccine that reproduced a naturally protective antibody pattern would be more likely to succeed than one that merely mimics the response seen in sick patients.

Methodologically, the peptide array approach has distinct strengths and limitations that shape how the results should be interpreted. Because the array presents short linear peptides, it detects antibodies directed against continuous epitopes but will miss responses that require conformational epitopes, the three-dimensional shapes formed when distant parts of a protein fold together. Many potent neutralizing antibodies in other infectious diseases target conformational epitopes, so the 283 immunogenic proteins identified here should be viewed as a floor rather than a ceiling on the antibody-targetable proteome. On the other hand, the peptide format offers resolution that full-length protein arrays cannot match: because each protein is tiled in overlapping fragments, researchers can pinpoint roughly where along a protein sequence the antibody response concentrates, information that is immediately useful for designing diagnostic antigens, mapping epitopes, and constructing subunit vaccine components. The proteome-wide, unbiased coverage also means that proteins absent from laboratory-adapted parasite lines or difficult to express recombinantly are not systematically excluded, a persistent problem in malaria antigen discovery.

The practical payoff of this resource is likely to unfold along three tracks. First, diagnostics: serological tests that detect exposure to P. vivax depend on antigens that are reliably recognized across populations and infection histories, and the validated list of commonly immunogenic proteins provides a vetted menu from which such antigens can be selected. Second, vaccine development: invasion-associated proteins and the protective PIR responses in asymptomatic carriers give candidate-selection pipelines concrete biological rationale rather than guesswork. Third, surveillance and elimination: as malaria programs push toward regional elimination, distinguishing people with recent blood-stage infection from those with historical exposure, and identifying asymptomatic reservoirs that sustain transmission, requires exactly the kind of antigen panel this study delivers. The authors frame the dataset explicitly as a community resource intended to accelerate all three of these efforts for a pathogen that has historically lagged behind P. falciparum in research investment.

What makes the work resonate beyond the vivax community is the demonstration that proteome-scale epitope mapping is now feasible for a human parasite whose proteins are notoriously hard to study by conventional means. A single experiment, requiring only synthetic peptides and a few dozen serum samples, produced a comprehensive census of the antibody-visible proteome, including dozens of proteins no one had thought to test. For a disease that puts 2.5 billion people at risk and generates 10 million clinical cases annually, converting that census into better diagnostics, validated protective markers, and rational vaccine candidates is the urgent next step, and the map produced here gives researchers everywhere a common starting point for the journey.

Subject of Research: Proteome-wide mapping of antibody responses to Plasmodium vivax proteins using a high-density peptide array

Article Title: Proteome-wide characterization of Plasmodium vivax antigens using a high-density peptide array

Article References: Asawa, R., Hazzard, B., Ko, K., Tebben, K., Tan, J., Cantaert, T., Berry, A., Tolia, N., Popovici, J., & Serre, D. (2026). Proteome-wide characterization of Plasmodium vivax antigens using a high-density peptide array. PLOS Pathogens, 22(9), e1014621. https://doi.org/10.1371/journal.ppat.1014621

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014621

Keywords: Plasmodium vivax, malaria, peptide array, antibody response, immunogenic proteins, erythrocyte invasion, PIR proteins, asymptomatic infection, vaccine candidates, serological markers, proteomics, PLOS Pathogens

The team, led by Carl C. Crodel and Inken Hilgendorf, enrolled 114 patients between July and September 2022 and followed them up one year later. The cohort had a median age of 62 years, with ages ranging from 27 to 70, and included 55 women, or 48.2 percent of participants. Rather than relying solely on hospital records, the investigators combined retrospective chart review with a questionnaire that captured each patient’s vaccination status, any side effects experienced, and the course of any COVID-19 illness that occurred. This dual approach allowed them to assess not just laboratory measures of immunity but also the real-world tolerability of vaccination in a group whose immune systems are still rebuilding after transplantation.

Vaccine uptake in the cohort was high but not universal. Overall, 89.4 percent of patients had received at least two doses of a SARS-CoV-2 vaccine, and 66.7 percent had completed three vaccinations. A notable minority, 10.5 percent, refused vaccination altogether, a finding that underscores lingering hesitancy even among patients at elevated risk of severe disease. The mRNA vaccines dominated the vaccination landscape in this cohort, consistent with their widespread use across Germany during the pandemic. Because mRNA vaccines deliver the genetic instructions for the viral spike protein directly into host cells, they depend on the recipient’s own cellular machinery to produce antigen and on intact antigen-presenting cell function to prime T cells, both of which can be compromised in the months following transplantation.

The central immunological finding was encouraging. Most patients responded to vaccination, with 81.8 percent reaching detectable SARS-CoV-2 spike IgG titers after the second dose and 96.1 percent achieving seroconversion after the third. The spike protein, the surface molecule the virus uses to enter cells via the ACE2 receptor, is the principal target of neutralizing antibodies induced by all currently licensed vaccines, so anti-spike IgG levels serve as a widely used proxy for protective humoral immunity. The jump in response rates between the second and third doses suggests that a two-dose primary series is insufficient for many transplant recipients, and that a booster dose plays a genuine immunological role rather than being merely a formality.

One of the most clinically actionable results concerns timing. Patients who were vaccinated within 24 months of their transplant had significantly lower anti-spike IgG levels than those vaccinated later, a difference that reached statistical significance with a p-value of 0.017. This finding aligns with the known kinetics of immune reconstitution after allogeneic transplantation, in which B cell recovery and the re-establishment of functional B cell repertoires can take one to two years or longer. During this window, newly generated B cells are still learning to respond to new antigens, and the donor-derived immune system may not yet have fully replaced the recipient’s lymphocytes. Delaying vaccination, when clinically feasible, may therefore allow the immune system to mature enough to generate a stronger antibody response.

Safety data from the study were similarly reassuring. The most common side effect was pain at the injection site, reported by 34 percent of patients, followed by limb pain in 17 percent and swelling in 14 percent. These rates are broadly comparable to those seen in the general population and in other immunocompromised groups, and no alarming safety signals emerged. For clinicians counseling transplant recipients who may worry that vaccination could trigger graft-versus-host disease flares or other complications, these data provide a concrete evidence base for recommending vaccination as feasible and well tolerated. The authors concluded that vaccination in this population is both safe and effective, with the timing of administration relative to transplantation emerging as the key modifiable factor influencing immune response.

The study’s design has both strengths and limitations worth noting. By combining hospital records with patient questionnaires, the investigators captured a fuller picture of the vaccination experience than either source alone would provide, including self-reported side effects that might never appear in clinical documentation. The one-year follow-up also allowed assessment of longer-term outcomes rather than just immediate post-vaccination antibody titers. On the other hand, the cohort size of 114 patients, while respectable for a single-center transplant study, limits the statistical power to detect subtle subgroup effects, such as differences by donor type, conditioning regimen, or the degree of immunosuppression. The observational design also means that the association between vaccination timing and antibody levels, however biologically plausible, cannot be taken as proof of causation without randomized or prospective confirmation.

The findings arrive at a time when COVID-19 vaccination policy for immunocompromised populations continues to evolve. Many national guidelines already recommend additional vaccine doses for severely immunocompromised individuals, and this study provides direct evidence supporting that approach specifically for allogeneic transplant recipients. The near-universal seroconversion after three doses, reaching 96.1 percent, argues for ensuring that transplant recipients complete at least a three-dose series, while the timing effect suggests that clinicians and patients may reasonably weigh the benefits of earlier protection against the prospect of a stronger response if vaccination can be deferred until more than two years after transplantation. In practice, the risk of SARS-CoV-2 exposure during the waiting period will often tip the balance toward earlier vaccination, but the study gives clinicians a quantitative basis for that conversation.

Beyond its immediate clinical implications, the study contributes to a broader understanding of how the reconstructed immune system of a transplant recipient handles novel antigens. Allogeneic transplantation effectively resets the adaptive immune system, replacing it with donor-derived lymphocytes that must re-educate themselves in a new host environment. How quickly this new immune system can respond to vaccination reflects the pace of thymic output, B cell lymphopoiesis, and the establishment of functional immune cell communication. The Jena team’s observation that responses improve with time since transplant and with additional doses fits neatly into this framework and suggests that the same principles may apply to other vaccines, from influenza to newer respiratory syncytial virus immunizations, in this growing population of long-term transplant survivors.

As the number of allogeneic stem cell transplant survivors continues to grow worldwide, evidence-based vaccination strategies tailored to their unique immunology become increasingly important. This study, conducted without external funding and published open access, adds a valuable European dataset to the literature, confirming that mRNA vaccination against SARS-CoV-2 is feasible, well tolerated, and largely effective in transplant recipients, while highlighting that the third dose and the interval since transplantation are the factors that matter most. For the patients themselves, the message is one of cautious optimism: their rebuilt immune systems can indeed learn to recognize and respond to a virus they had never encountered, provided the vaccine is given the time and the doses it needs to do its work.

Subject of Research: Long-term humoral immune response and safety of SARS-CoV-2 mRNA vaccination in allogeneic haematopoietic stem cell transplant recipients

Article Title: Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation

Article References: Crodel, C. C., Gork, L., Göpel, W., Linke, P., Sinn, K., Miethke, J., Hochhaus, A., & Hilgendorf, I. (2026). Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06632-4

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06632-4

Keywords: allogeneic stem cell transplantation, SARS-CoV-2, vaccination, mRNA vaccines, antibody response, immunogenicity, immunocompromised patients, COVID-19, immune reconstitution, booster dose, haematology, oncology